Conference Presentation, Interview
Dr. Michael Mina of the Harvard T.H. Chan School of Public Health
- The virus is projected to maintain a "sweet spot" of high transmissibility and low virulence similar to the 1918 flu, driven primarily by accumulated mild cases rather than super-spreading events, with genetic shifts expected to follow normal seasonal coronavirus mutation rates and remain largely stable.
- Current U.S. mortality rates are anticipated to be high due to limited testing capacity and healthcare surge constraints, particularly a lack of ventilators, while the true global mortality rate is estimated between 0.1% and 1% with a central estimate around 0.3% or 0.4%.
- Transmission patterns in warmer climates remain uncertain due to a fully susceptible population, though droplets may become a larger driver than aerosols; immunity is estimated to last 6 to 18 months, potentially leading to frequent cycles and reinfection.
- Without successful mitigation to achieve herd immunity or a vaccine, the virus is expected to follow a drawn-out course with potential peaks in the fall if summer reduction does not occur, though the R0 is likely to be driven below 1 within the next couple of weeks.
- Testing capacity in the U.S. faces significant reagent shortages and is projected to plateau around 20,000 tests per day until Roche reagents arrive, with turnaround times facing two-to-four-day delays and point-of-care tests potentially becoming available in one to two months.
- The sensitivity of current testing is expected to be 70% to 80% due to sampling procedure misses, while asymptomatic or mild transmission is considered a major route of spread, and the vast majority of infections will remain mild and unreported.
- Standard of care remains supportive without a routine antiviral, though IL-6 inhibitors show potential benefits, and remdesivir could be beneficial if it reduces hospital stays by one-fifth to one-sixth; monoclonal therapeutics are expected to be the first true antiviral class to show benefit.
- Vaccine availability via RNA technology is projected in 12 to 15 months subject to biological validation, but there is a risk of antibody-dependent enhancement similar to dengue, and a significant likelihood of private companies launching expensive, unvalidated home test kits.
- Healthcare systems face continued depletion of PPE stocks, likely forcing administrators to relax safety requirements and potentially endangering employees, while hospitals will continue to struggle with the implications of healthcare infrastructure capacity.